Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefania Scala

Showing results (51-60 of 124) with videos related to

Pageof 13
Sort By:
Cancers|August 30, 2020
Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective StudyClaudia von Arx, Giuseppina Rea, Maria Napolitano, et al.
Neoplasia (New York, N.Y.)|January 12, 2013
IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironmentFabrizio Mattei, Giovanna Schiavoni, Paola Sestili, et al.
International Journal of Molecular Sciences|May 24, 2016
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue TypesGiosuè Scognamiglio, Anna De Chiara, Maurizio Di Bonito, et al.
International Journal of Surgery (London, England)|July 1, 2015
Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome itMonica Capozzi, Ieranò Caterina, Chiara De Divitiis, et al.
Frontiers in Bioscience (Elite Edition)|December 29, 2009
"CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression"Renato Franco, Gerardo Botti, Massimo Mascolo, et al.
European Urology|October 16, 2010
Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3Sisto Perdonà, Vitor Cavadas, Giuseppe Di Lorenzo, et al.
Cancer Immunology, Immunotherapy : CII|April 6, 2007
CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell typeStefania Scala, Caterina Ieranò, Alessandro Ottaiano, et al.
Journal of Cellular and Molecular Medicine|April 1, 2015
Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1Luisa Circelli, Valeria Ramundo, Vincenzo Marotta, et al.
Anticancer Research|July 26, 2024
Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control StudyMara Caroprese, Manuel Conson, Angela Barillaro, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2012
Inhibition of stromal CXCR4 impairs development of lung metastasesCrescenzo D'Alterio, Antonio Barbieri, Luigi Portella, et al.
Pageof 13

Showing results (51-60 of 124) with videos related to

Sort By:
Pageof 13
Cancers|August 30, 2020
Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective StudyClaudia von Arx, Giuseppina Rea, Maria Napolitano, et al.
Neoplasia (New York, N.Y.)|January 12, 2013
IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironmentFabrizio Mattei, Giovanna Schiavoni, Paola Sestili, et al.
International Journal of Molecular Sciences|May 24, 2016
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue TypesGiosuè Scognamiglio, Anna De Chiara, Maurizio Di Bonito, et al.
International Journal of Surgery (London, England)|July 1, 2015
Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome itMonica Capozzi, Ieranò Caterina, Chiara De Divitiis, et al.
Frontiers in Bioscience (Elite Edition)|December 29, 2009
"CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression"Renato Franco, Gerardo Botti, Massimo Mascolo, et al.
European Urology|October 16, 2010
Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3Sisto Perdonà, Vitor Cavadas, Giuseppe Di Lorenzo, et al.
Cancer Immunology, Immunotherapy : CII|April 6, 2007
CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell typeStefania Scala, Caterina Ieranò, Alessandro Ottaiano, et al.
Journal of Cellular and Molecular Medicine|April 1, 2015
Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1Luisa Circelli, Valeria Ramundo, Vincenzo Marotta, et al.
Anticancer Research|July 26, 2024
Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control StudyMara Caroprese, Manuel Conson, Angela Barillaro, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2012
Inhibition of stromal CXCR4 impairs development of lung metastasesCrescenzo D'Alterio, Antonio Barbieri, Luigi Portella, et al.
Pageof 13